Recent studies have showed estimations of worldwide 50 million cattle infections with M. bovis, at a cost to the agricultural community of 2-3 billion € per year. In developing countries, M. bovis infection is still widespread, in both cattle and humans. Even in developed countries, successful eradication of disease from livestock is hampered by the presence of wildlife reservoirs of M. bovis. Under these circumstances, a single case of a reportable disease in livestock can result in serious economic consequences for the producer, public, and governments. Within this scenario, there’s room and clear business opportunities for integrated control products or solutions that aim at addressing what is considered a global problem, animal tuberculosis. Our overall objective is therefore to take the results of the TB-STEP project - “Strategies for the eradication of bovine tuberculosis”, funded under FP7-KBBE-2007 with project number 212414, where most of the WildTBVac partners were involved, and build a pre-commercial set of TB control solutions by means of testing the technical and economical viability of the aforementioned integrated approach. WildTBVac specific objectives are the following:• To standardize and optimize the production of a TB Vaccine (prototype resulting of the TB-STEP project)• To evaluate several vaccine-compatible diagnostic strategies (also resulting from the TB-STEP project) that will include multi-species DIVA tests (wild boar, domestic pigs, cattle)• To assess the field efficacy of integrated TB control strategies including oral vaccination for TB control in wild boar• To evaluate the field efficacy of integrated TB control strategies including oral vaccination for TB control in domestic and feral pigs• To define the exploitation and commercialization strategy including clear technology transfer approaches and development of a market oriented business.